Human Recombinant Epidermal Growth Factor to accelerate the healing after chemical peels”.

Center for Genetic Engineering and Biotechnology (CIGB), in Havana.0 个研究点目标入组 30 人开始时间: 2011年5月3日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment

•1.Informed consent. 2.Age major than 20 years old, both sexes. 3.Skin diseases that affect facial aesthetics and require peel. 4.Fitzpatrick skin type classification I to IV.

•1.Active lesions of acne vulgaris that require treatment or patient with them in the last 6 months. 2.Fitzpatrick skin type classification V-VI. 3.Infection requiring antibiotic treatment or active herpes virus infection. 4.Another skin disease affecting the face. For example: neurotic excoriation. 5.Personal history of keloids or others defect of healing. 6.Diabetes mellitus, erythematosus lupus or some others systemic disease that concern general compliance (liver disease, renal disease, pancreatic disease, colagenosis, anemia, etc.). 7.Malignancies (except the basal cell carcinoma and the cervix cancer in situ after surgery and complete cured). 8.Serious hypertension or heart disease. 9.Previous treatment with steroids in the last 3 months. 10.Previous treatment with EGF in the last 30 days. 11.Previous treatment in the last 6 months like this: isotretinoin, chemical peels, aesthetic or surgical procedure of the head or neck. 12.Serious psychiatric disorder and other disease that limit informed consent. 13.Patient exposed to ultraviolet radiation due to their occupation. 14.Pregnancy and lactation.

发起方

Center for Genetic Engineering and Biotechnology (CIGB), in Havana.